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ABSTRACT
Glioblastoma Multiforme (GBM) is the most lethal subtype of glioma (brain tumor), with
a 5-year survival rate of merely 5.6% post diagnosis 1. The traditional study of glioblastoma has
investigated the role of multiple genes in advancing its progression, including the upregulation of
Epidermal Growth Factor Receptor (EGFR). However, there is at yet little research into the
epigenetic factors that control EGFR, both in the precursor astrocytes and in glioblastomas
themselves2. EGFR and its regulation may play a significant role in the progression and
development of GBM from astrocytes. Through modification of genomic pathways as observed
in GBM, our lab generated an in vitro glioblastoma model that is representative of the pathways
modulated in glioblastoma. The purpose of this study was to investigate the modulation of
epigenetic factors that occurs upon conversion from astrocyte to glioblastoma-like cells using
epigenetic and expression analysis methods, in hopes of revealing potential therapeutic venues
for future study. The study revealed that activating marks present in astrocytes were in fact
downregulated in the glioblastoma cells leading to decreased expression of wild-type EGFR
mRNA. Further exploration may provide more clues as to why this modulation occurs.
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INTRODUCTION
Glioblastoma Multiforme (GBM) is considered the most common and most malignant
form of glioma, falling into the classification of Type IV/IV tumors. Currently, 5 to 6 in 100,000
individuals are diagnosed with primary malignant brain tumors. GBM accounts for 47.7% of
primary malignant brain tumors with a projected total 31,990 cases in 2019 1. 90% of gliomas
arise from normal glial cells (considered primary gliomas), whereas 10% arise from previously
existing low-grade astrocytoma (considered secondary gliomas). Secondary gliomas tend to have
a better prognosis and grow less quickly than the primary gliomas, but while they differ in origin,
both types of glioma are similar in morphology3. GBM has a poor prognosis, with a 5.6% 5-year
survival rate and a median survival time of 15 months 1,3,4,5. The mean age of diagnosis is
typically around 64 years, with a greater occurrence in men than women 3. GBM prevalence
increases with age, though around 100 cases diagnosed each year are of children under 15 years
old1.
Unfortunately, the etiology of GBM is poorly understood. Though a familial form of
GBM has been described, it differed in the genetic background from 99% of the cases described,
which are believed to arise spontaneously. There are environmental factors that correlate with
increases in glioblastoma prevalence in a population—these include exposure to workplace
hazards such as pesticides, petroleum refinery or compounds used in synthetic rubber
manufacturing. Ionizing radiation is potentially the most important environmental risk factor for
GBM development3,4.
On a physiological level, glioblastoma is commonly believed to originate from
astrocytes, a type of glial cell, giving them the secondary name of astrocytoma. Glioblastomas
1

are characterized by high levels of vascularization and minimal metastasis, theoretically due to
the Blood-Brain Barrier inhibition of intravasation and the rapid progression of the disease. Also,
“infiltrating growth” is a characteristic feature of GBM, meaning that the cells grow outwards
and in between neighboring neurons, leading to interference with synaptic connections 4,5,6.
Studies have found that in cancerous cells associated with primary glioblastomas, genes such as
CDKN2A, MDM2, and EGFR are activated, all of which play roles in pathways that control cell
growth and proliferation7,8. Though multiple subtypes of glioblastoma exist as defined by
molecular and genetic analysis, EGFR amplification is still widely observed throughout 6,8.
Typically, GBM manifests symptomatically as headaches, ataxia and vision disturbances
due to its interference with the normal functioning of the brain, leading to common misdiagnosis
at first. In addition to these symptoms, the rapid and infiltrating growth of the tumor can lead to
an increase in intracranial pressure and, on occasion, hydrocephaly (a build-up of fluid in the
ventricles of the brain, further increasing intracranial pressure). Confirmation requires diagnosis
primarily through Magnetic Resonance Imaging (MRI), though other techniques may be used as
well, including functional MRIs, perfusion imaging, and positron-emission tomography.
Typically, diagnosis occurs once the tumor has reached around 5 cm in size 3,4.
Due to the size of the tumor at the time of diagnosis, the standard of treatment begins
with surgery for removal. In cases where full removal is not possible, resection surgery is
considered coupled with radiation therapy, with both chemotherapy and radiation therapy being
maintained before and after surgery. Chemotherapy drugs are limited in number, and the most
commonly used FDA-approved treatment is the drug Temozolomide, which allows for tailoring
to the specifications of the patient. However, recent studies have shown that genetic and
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epigenetic modifications (such as promoter methylation of the gene MGMT) increase the ability
of glioblastomas to become resistant to Temozolomide, suggesting that a deeper understanding
of the disease is needed to generate a better therapy8. Radiotherapy can also be better resisted by
the glioma stem cells due to their ability to activate DNA-damage repair pathways, enhancing
their resistance to treatment. The more recent FDA approval of the use of Bevacizumab for
glioblastoma treatment raised hopes over a new treatment model, but multiple FDA clinical trials
showed it was mainly beneficial for recurrent GBM. While over 90 clinical trials for
Glioblastoma are underway, few have gotten the results necessary to move them towards FDA
approval. Further investigation of the GBM gene expression could allow for better-targeted
therapies that would show improvements in treatment efficacy and localization 9,10.
The upregulation of wild-type EGFR or Epidermal Growth Factor Receptor has been
documented as a common occurrence upon genetic analyses of GBM samples 4,6-8,14,15. EGFR
was the first identified receptor tyrosine kinase and plays an essential role in cell signaling and
proliferation. With a molecular weight of 170 kDa, EGFR possesses an intracellular tyrosine
kinase domain, which dimerizes upon interaction with its ligand, Epidermal Growth Factor
(EGF). Though EGFR maintains many interactions that initiate cellular changes, two major
pathways play a role in increasing cellular growth and proliferation 11.
The first pathway is commonly known as the RTK pathway. Binding of EGF to the
extracellular domain of the EGF receptor initiates the autophosphorylation of the receptor’s
intracellular tyrosine residues. These phosphorylated tyrosine sidechains encourage the binding
of nearby signaling molecules, such as phospholipase Cγ (PLCγ). The binding of PLCγ to EGFR
initiates PLCγ’s tyrosine phosphorylation, which allows it to catalyze the breakdown of
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phosphatidylinositol-4,5-bisphosphate (PIP 2) into diacylglycerol (DAG) and inositol 1,4,5trisphosphate (IP3). DAG production activates protein kinase C (PKC) which initiates a signaling
pathway leading to the transcription of cell proliferation genes 11,12.
EGF binding can also initiate interactions with Grb2 and the phosphorylated tyrosine
residues. Grb2 associates with Sos (a Ras pathway protein) and then binds to the EGFR
intracellular domain, which provides the energy for Sos to convert the nearby Ras protein’s GDP
to a GTP, activating it. Ras can then go on to initiate the Ras signaling pathway, which
ultimately activates transcription factors like c-Myc (which transcribes genes involved in cell
proliferation). Other molecules besides Grb2 can also utilize similar mechanisms to activate the
Ras signaling pathway through interaction with EGFR 11,13.
In a normal human Central Nervous System, EGFR plays important roles in development
and differentiation. Its ligand, EGF is detectable throughout adult rat brain tissue, and its mRNA
was detectable by embryonic day 14, with levels maintained through birth. EGFR is similarly
maintained through adulthood in cerebellar Purkinje cells and cells in the cerebral cortex. In
contrast, rat astrocytes expressed EGFR around day 16 postnatal, but the levels decreased around
day 30 and were undetectable around two months (an age commonly considered as an adult in
rodent models). As such, the results suggest that the expression of EGFR in the brain varies by
cell type, and in astrocytes, EGFR expression disappears by adulthood 11.
EGFR amplification was observed in 97% of the classical subtype of GBM
(corresponding with primary de novo GBM) in a study published in 2010 8. Much of the research
into EGFR amplification in GBM has focused on point mutation generation and the development
of variants7-9,14—however, the results of these studies have not allowed for breakthroughs in
4

therapeutic EGFR targeting, as attempts to target wild-type EGFR through RNA interference and
Tyrosine Kinase Inhibitors (TKIs) have failed to induce cell death 8,14.
Based on data generated by The Cancer Genome Atlas (TCGA), our lab aimed to create a
model for glioblastoma that represented the genomic basis of the disease more accurately. Three
pathways are generally affected in the development of GBM— the p53 and RB tumor
suppression pathways (which are inhibited) and the RTK signaling pathway (which is amplified
and can be initiated by EGFR). In 74% of cases documented by TCGA, all three of these
pathways contain a modification15.
Our lab modeled this phenomenon by viral transduction of a glial-cell culture with two
vectors—one coding for a CDKN2A shRNA that effectively inhibits (>95% knockdown) both
tumor suppression pathways, and another containing EGFR variant III (EGFRvIII) an isoform of
EGFR that constitutively activates the RTK pathway. The introduction of these genes into glial
cultures induced oncogenic transformation, and the formation of tumor-like colonies. This in
vitro model of glioblastoma can therefore be utilized to investigate the conversion-mediated
upregulation of EGFR. Though the glioblastoma model has been characterized through genomic
analysis, insight into its epigenome has yet to be established.
The study of epigenetics involves the analysis, at the molecular level, of modifications to
DNA that alter gene expression without modifying the DNA sequence. At a broad level, this
includes miRNA and other interference systems but mostly pertains to direct modifications to the
chromatin structure17,18.
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In eukaryotic cells, DNA exists in a highly coiled chromatin structure, with the smallest
organized unit known as a nucleosome. Nucleosomes are composed of DNA wrapped 1.2 times
around a histone protein (a positively charged eight-subunit protein with protruding tails) with
segments of DNA not bound to the histone directly connecting two nucleosomes. In its most
extended form, DNA appears like “beads on a string,” with a width of 10 nm. Regions of the
chromatin designated as “heterochromatin,” like telomeres and centromere regions, may always
be tightly coiled, preventing the possibility of transcription occurring at those sites 19. Other
regions may vary in the density of coiling based on specific epigenetic markers.
One major epigenetic marker is DNA methylation. The methylation of the DNA
backbone causes an increase in DNA coiling at that site, which can block regulatory regions.
Enzymes such as DNA methyltransferases introduce DNA methylation, while TET enzymes
decrease DNA methylation. In promoter regions that regulate transcription, DNA methylation
can lead to reduced expression18.
Another way chromatin density can be impacted is through modification of the
aforementioned histone tails. The addition of different organic compounds can modify the
interactions of these histone tails with the DNA, modifying the coiling of the DNA strand around
the histone protein itself. The Histone 3 (H3) subunit tail is particularly well studied for these
modifications. H3 Lysine-27 Trimethylation, for instance, results in transcriptional inhibition. H3
Lysine-27 Acetylation, on the other hand, results in increased transcription of the neighboring
gene20. These modifications dramatically impact the expression of genes and ultimately play a
role in monitoring the genome’s adaptive responses to environmental stimuli.
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The epigenetic landscape of EGFR is poorly understood. Data generated as a part of the
ENCODE project21 has allowed for basic characterization of the EGFR sequence (Figure 1).
However, in-depth analysis of specific cell types has been limited to non-neural cells.

Figure 1. Pictorial representation of Mouse Genome Database’s EGFR epigenetic landscape 21. Compiled
data was obtained from histone mark analysis of P0 hindbrain/midbrain/forebrain samples and bisulfite
sequencing of Embryonic Stem/Neural cells. No histone mark or DNA methylation data is currently
available from mouse glial or glioblastoma cultures.
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The 866 bp CpG Island contains 80 CpG moieties, with minimal methylation in
Embryonic Stem Cells and Neural Cells. The presence of H3K4me2, H3K4me3 and H3K27Ac
marks in the regulatory region upstream from the coding region suggests these play a role in
activation of EGFR in P0 mouse brains. Other histone post-translational modifications that have
been analyzed were found to have negligible occupancy at the promoter site in these samples 21.
Most research on EGFR expression has focused on transcriptional factors, with few
conclusions made regarding its upregulation in GBM 15,16,20. A recent study analyzed human
patient SVZ brain samples from normal and glioblastoma patients and found that DNA
methylation patterns did not differ in adult SVZ from both sets—it was constitutively
hypomethylated in both samples. In addition, H3 Lysine-4 Trimethylation (H3K4Me3) and H3
Lysine-27 Acetylation (H3K27Ac) were activating marks found in cells actively expressing
EGFR, and not in the adult non-neoplastic samples 22. However, current research has not explored
the differences in epigenetic modifications between precursor astrocytes and glioblastoma cells
in vitro.
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METHODS
Mouse astrocytes were obtained through primary culture. The glioblastoma-like culture
was generated through Lentiviral transduction of astrocytes with two plasmid constructs
containing EGFR variant III and an shRNA to knockdown CDKN2A expression respectively.
Astrocyte and cancer-like cells were maintained in DMEM with 10% FBS and 1%
Penicillin/Streptomycin. Cells were maintained through passaging with Trypsin-EDTA.
To obtain mRNA expression data, RNA extraction using TRIZOL (Invitrogen). The
extracted RNA was converted to cDNA using the GenDepot Amfirivert Platinum cDNA
synthesis kit and according to the manufacturer’s conventional protocol. Oligo-dT was used as a
primer in synthesis of the complementary DNA. The cDNA was then analyzed through
quantitative PCR, using SYBR green reagent and gene specific primers (Table 1).
To analyze the methylation status of the gene, bisulfite sequencing was performed.
Conversion of genomic DNA to bisulfite DNA was performed using the EZ DNA methylation
kit from Zymo Research and following the manufacturer’s protocol. The CpG island was then
amplified through PCR with gene specific primers (generated with conversion of C to U to
mimic modification during sulphonation—see Table 1). The product was ligated into the pGEMtEasy vector, then cloned in DLX5ɑ Escherichia coli cells. Cells were spread on ampicillin plates
for resistance selection. Cloned and properly ligated colonies were identified using blue-white
screening. Viable colonies were cultured in Luria-Bertani broth for DNA extraction using the
GeneWiz miniprep kit and protocol. Extracted plasmids were sent for sequencing to determine
extent of methylation- methylation would result in the maintenance of Cytosines in the sequence,
as opposed to the generation of Uracils (sequenced as Thymines). Ten colonies were analyzed
for both astrocytes and one cell line (TFII) to ensure accurate comparisons were made.
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Chromatin immunoprecipitation (ChIP) was performed for four major markers—Histone
3 Lysine 4 dimethylation (H3K4me2), Histone 3 Lysine 4 trimethylation (H3K4me3), Histone 3
Lysine 9 acetylation (H3K9ac), and Histone 3 Lysine 27 acetylation (H3K27ac). Similar
numbers of cells were obtained for astrocytes and glioblastoma-like cell samples. Cells were
lysed and sonicated, then pre-cleared with 50 μL of Salmon Sperm A agarose slurry, 1% protease
inhibitor (ChIP dilution buffer was used to bring the volume up to 5 mL). The sample was
extracted from the slurry via centrifugation at 100g for 1 minute, and 1/100 th of the sample was
set aside as the input. The remaining sample was divided into 5 900 μL volumes, and specific
antibodies (1 μg) were introduced for pull down. Samples were washed in the order that
follows—Low Salt Buffer, High Salt Buffer, Lithium Chloride Buffer, and Tris/EDTA twice
(see Appendix A for composition). Washing was performed on a rotator at 4 degrees Celsius for
5 minutes, then tubes were spun down at 100 x g for 1 minute and the solution was removed.
Samples were then eluted for 15 minutes twice in 100 μL increments of a solution of 10%
sodium bicarbonate and 10% sodium dodecyl sulfate (SDS). Reverse crosslinking was performed
with the addition of 8 μL of 5M NaCL at 65 degrees Celsius overnight, followed by RNA
digestion at 37 degrees Celsius for 0.5 hours and protein digestion at 45 degrees Celsius for 2
hours. DNA isolation was performed with phenol chloroform and eluted in 20 μL of DNase-free
water. Isolated DNA was amplified at the EGFR locus using PCR. Densitometric analysis was
performed following gel imaging. The following antibodies were used: H3K4me3 (1 mg/mL),
ab8580, Abcam; H3K27ac (1 mg/mL), ab4729, Abcam; H3K4me2 (1mg/ml), ab7766, Abcam;
H3K9ac (1 mg/mL); Normal mouse IgG (1 mg/mL), 12-371, EMD Millipore Corp.
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EGFR Expression forward primer

EGFR Expression reverse primer

EGFR Bisulfite DNA amplification forward
primer

EGFR Bisulfite DNA amplification reverse
primer

EGFR Chromatin Immunoprecipitation forward
primer

EGFR Chromatin Immunoprecipitation reverse
primer

AACTGCCCATGCGGAACTTA

59.96

ACGACAGCGATGGGAACATT

60.04

CTTTCGCGGGTGTGTAGTTG

59.49

ATGCCTAAGAGGCGGAATCG

59.97

CCTCCTCTTCTTCCCGCACTGT

63.96

TGGCTCTGGCTCTCCGGGATTA

64.96

Table 1. Primers and melting temperatures used for expression and ChIP analyses.
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RESULTS
SYBR Green qPCR of synthesized cDNA from Astrocyte and Tumor Cell Line RNA
samples was performed as described in the methods section. Normalization was performed to
beta actin via calculation of ΔCT. Values were averaged, then fold change of EGFR expression
was determined based on astrocyte samples. As can be seen, the data shown below reflects a
significant reduction in EGFR expression (p < .01) upon creation of the tumor cell line, contrary
to our original hypothesis. The tumor cell line samples studied here were contaminated with
HEK-293T cells, which is further discussed below. This may have contributed to the reduction

Fold Change Expression of Astrocyte to
Tumor Cell Line, Normalized to Beta
Actin

seen in expression of EGFR.

Normalized mRNA expression of EGFR in
Astrocyte and Tumor Cell Line samples
***

1.2
1
0.8
0.6
0.4
0.2
0
Astrocyte

s

Tumor Cell Line

Cell Sample Type

Figure 2. Expression Data obtained via quantitative PCR of Astrocyte and Tumor Cell Line mRNA. qPCR was
performed with Astrocyte and Tumor Cell Line cDNA. Beta Actin was also run alongside EGFR to ensure
functionality of data. Significance was calculated using a 2-tailed parametric t-test comparison of ΔCT values, p =
.0058.
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To determine if epigenetic modulation of mouse cells was in part responsible for the
observed reduction, Chromatin Immunoprecipitation (ChIP) was performed in both Astrocyte
and Tumor Cell Line samples against four histone post-translational modifications as described
in the methods section. Densitometric analysis of histone post-translational modifications in the
EGFR promoter region revealed a significant reduction in the glioblastoma samples for
activating marks H3K27ac and H3K4me3 (Figure 3), contrary to our original hypothesis.

Mark Prevalence Around Promoter
(Normalized to Input)

Distribution of Activating Histone PTMs across Promoter Region of EGFR
in Astrocyte and Tumor Cell Line samples
**
n.s

1.6000
1.4000

**

1.2000
1.0000
0.8000

n.s

0.6000
0.4000
0.2000
0.0000
-0.2000

Tumor Cell Line
Astrocyte
Mark Prevalence Around Promoter (Normalized to Input) (n=3)
H3K9ac

H3K27ac

H3K4me3

H3K4me2

Figure 3. Post-Translational markers for Histone Modifications in Tumor Cell Line versus mouse precursor
Astrocytes. 4 activating marks were analyzed—Histone 3, Lysine-9 acetylation (H3K9ac), Histone 3, Lysine-27
acetylation (H3K27ac), Histone 3, Lysine-4 trimethylation (H3K4me3), and Histone 3, Lysine-4 dimethylation
(H3K4me2). Significance was determined with a 2-tailed parametric t-test, ** = p < .05.
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Methylation data, obtained (as described in the Methods section) via bisulfite sequencing,
is shown below (Figure 4). On the left, the CG repeats present in the CpolyG island of EGFR are
represented in red. On the right, ten colonies and their first 60 CG moieties are represented with
circles. As can be seen from comparison of Astrocyte and Tumor Cell line methylation
(represented by filled in circles), there is insufficient evidence that any difference between the
methylation levels of the two cell types exists.

Figure 4. Methylation data for EGFR’s CpG Island. Region to the left represents all CpG moieties (highlighted in
red). Region to the left reflect the methylation status of the first 60 CpG moieties identified—an open circle means
no methylation is present, while a closed circle means methylation occurred. 10 colonies were analyzed for both cell
types.
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DISCUSSION/CONCLUSION
Analysis of the collated data revealed a significant reduction in RNA expression of
EGFR in the glioblastoma-like culture as shown by qPCR, contrary to our original hypothesis.
This was reflected in the distribution of epigenetic marks— all four activating marks were
removed in the glioblastoma-like cell line, with the difference significant in H2K27ac and
H3K4me3 samples. Interestingly, presentation of activating marks and expression data were
obtainable for the precursor astrocytes, initially hypothesized to maintain minimal expression of
EGFR. There was no significant difference in the methylation status of the identified CpG island
between the astrocyte and glioblastoma cultures.
The data above depicts a different picture than was originally hypothesized would occur.
Astrocyte EGFR expression may occur on a different timeline than previously suggested. EGFR
expression in the tumor cell line may have been downregulated upon the addition of EGFR
variant III, a phenomenon that requires further investigation. It is also fascinating that, despite
the presence of a vast and modifiable CpG island, DNA methylation is rare and unutilized in the
studied astrocytes or the tumor cell line.
It is important at this time to note that during this study, it was determined that the mouse
tumor cell line samples were contaminated with human HEK-293T cells. While this finding may
not have affected the methylation or ChIP analysis (since the sequencing and PCR primers were
species-specific), this would have contributed to the reductions in EGFR expression that were
observed in the course of this analysis, as less mRNA would have been present from mouse cells
in the first place. Therefore, the findings require further investigation as discussed below.
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FUTURE WORKS
The collated data suggests several possible avenues for future analysis. First, it is critical
that the precise reason for the reduction in EGFR be ascertained, and the full extent of the
contamination’s effect be determined. This would involve isolation of mouse cells from the
HEK-293T cells and measuring the previously studied variables of mRNA and epigenetic
control. Should the contamination not be responsible for the differences in expression and
histone post-translational modification observed, further investigation into the regulation of
EGFR could be conducted as follows.
In this case, the presence of EGFR expression and activation in astrocytes, and its
subsequent reduction, could indicate EGFR plays a different role in the development of cancer
than previously hypothesized. Studying the root cause of this marked removal of activating
marks might provide some insight into regulation of EGFR upon oncogenesis. It was also
determined that DNA methylation is not indicated as a method of EGFR regulation in astrocytes,
a novel finding. In the future, investigation of the role CpG islands play in other cell types might
provide insight into how regulatory mechanisms differ upon differentiation.
Additionally, our data focused primarily on activating marks—however, other potentially
deactivating epigenetic markers may also play a role in the mechanism described. Therefore,
studying the addition of these marks may be a necessary step in further understanding the
process occurring in this conversion.
Establishment of expression and activating marks in the mouse astrocytes obtained
suggests that the epigenetic landscape of mouse astrocytes upon development requires further
study—their passaging in vitro, for instance, may not affect epigenetic landscape. Recent studies
have shown that certain genes can become up or downregulated in various cell types upon
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culturing via epigenetic modulation23-25, a factor that needs to be further analyzed in cell culture
conditions.
The introduction of EGFR variant III may interact with or impact expression of wild type
EGFR, something that has not been studied in the past. It may be necessary for further studies to
consider the impact of introducing EGFR variant III on wild type expression as a way to better
understand the cancer development.
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